CYP4V2

CYP4V2 encodes a member of the cytochrome P450 enzyme family, a group of proteins that chemically modify many different substances in the body. This particular enzyme is involved in processing fatty acid building blocks into certain polyunsaturated fatty acids. It works mainly in the retinal pigment epithelium (RPE), a support layer of cells behind the light-sensing retina that keeps photoreceptors healthy. When the enzyme does not work, fatty material builds up and the RPE and photoreceptor (definition: A light-sensing cell in the retina. Rods (used for night and peripheral vision) and cones (used for color and detail) are the two types.) cells gradually deteriorate. CYP4V2 is currently the only gene known to cause Bietti crystalline dystrophy. The condition is also written with the aliases BCD and CYP4AH1.

BCD is a progressive condition, meaning vision tends to change gradually over years. Many people first notice night blindness or a decline in sharpness of vision. Over time, degeneration of the retina and narrowing of the blood vessels that supply it lead to loss of central vision and visual field. A hallmark of the disease is tiny glistening crystal-like deposits in the retina, and many people also have similar crystals in the cornea, the clear front window of the eye. In one series of 16 Chinese patients, symptoms began between ages 12 and 44, and corneal crystals were present in all of them. In a large study of 164 patients, the average age at onset was about 30 years, and night blindness was the most common first symptom. Imaging studies have shown that both the retinal and the deeper choroidal blood supply are affected, with the choroidal layer sometimes affected more over time. The disease often progresses to legal blindness by about the fifth or sixth decade of life, though the pace and severity vary considerably from person to person.

It is well established that biallelic (two-copy) changes in CYP4V2 cause Bietti crystalline dystrophy, and the diagnosis can be confirmed with genetic testing. Across several cohorts, researchers have identified many different CYP4V2 variants, and a splice-affecting change often written as c.802-8_810del17bpinsGC is among the most common in Chinese patients. Studies have found that people carrying two truncating (protein-shortening) mutations tend to have earlier onset and progress to blindness at a younger age. A modeling study pooling data from untreated patients found that best-corrected visual acuity declines roughly linearly over time, with a steeper decline in people who already have reduced vision and longer disease duration. Distinctive imaging features such as outer retinal tubulation (small tube-like structures seen on retinal scans) are common in BCD and can help point toward the diagnosis. Because BCD has a recognizable appearance, it tends to be diagnosed more reliably by genetic testing than many other, more variable inherited retinal diseases.

Even among people with the same gene changes, the age of onset, pattern of crystals, and speed of vision loss vary widely, so a genetic result alone cannot predict an individual's future. Some unusual presentations have been reported, including macular edema, macular holes, and retinoschisis (a splitting of retinal layers), showing the disease can look different between family members. Rarely, affected relatives in the same family can show milder forms, and apparent dominant-looking inheritance has been described when parents are related, which can complicate the clinical picture. The exact way loss of the enzyme leads to crystal formation is still being worked out, though laboratory and animal studies point to abnormal lipid (fat) handling in RPE cells.

As of this review, there is no approved treatment that targets CYP4V2 or cures BCD. The most active area of research is gene replacement therapy, which uses a harmless modified virus (an adeno-associated virus, or AAV) to deliver a working copy of CYP4V2 to retinal cells. Early-stage human trials of several such products have reported that the injections were generally well tolerated, with mostly mild or moderate side effects related to the procedure or to steroid medication. Some participants showed improvement in visual acuity, but researchers have cautioned that early vision gains can partly reflect learning effects and test-to-test variation, so larger controlled studies are needed to confirm benefit. A review notes that two gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) products have progressed into Phase 3 trials, reflecting rapid development in this field. Separately, laboratory and animal studies, including gene-editing approaches and cell and zebrafish models, are exploring other ways to restore the enzyme's function, but these remain experimental and are not available treatments.

• First-in-human gene therapy trial

  Early-phase clinical trial

  What was found:

  The injections were generally well tolerated, with mostly mild or moderate side effects, and most treated eyes showed improvement in visual acuity.

  Why it matters:

  It is an early sign that delivering a working CYP4V2 gene to the retina may be safe and worth developing further.

  Limitation: It was small, had no control group, and improvements need confirmation in larger controlled studies.

• A gene therapy trial that urges caution in reading results

  Early-phase clinical trial

  What was found:

  No serious treatment-related safety problems were seen, and treated eyes improved, but the authors noted the gains were within test-retest variability and could partly reflect a learning effect.

  Why it matters:

  It shows the field is advancing while honestly flagging how hard it is to prove benefit in early, uncontrolled studies.

  Limitation: Small size, no randomization, and possible measurement artifacts limit firm conclusions about effectiveness.

• What goes wrong inside retinal cells

  Laboratory and animal research

  What was found:

  Fat droplets accumulated in RPE cells before retinal degeneration appeared, linked to disruption of a lipid-processing pathway (PPARα).

  Why it matters:

  It helps explain how loss of the enzyme leads to the crystal deposits and cell damage seen in BCD.

  Limitation: Findings in fish and cultured cells may not fully match human disease and do not represent a treatment.

• A large look at how BCD progresses

  Observational human cohort study

  What was found:

  The average age at onset was about 30 years, night blindness was the most common first symptom, and patients with two truncating mutations had earlier onset and faster progression to blindness.

  Why it matters:

  It gives a broad picture of how the disease develops and shows that the type of mutation can influence severity.

  Limitation: It describes a single large cohort at one point in time and cannot predict any individual's course.

• Modeling vision loss over time

  Meta-analysis of human data

  What was found:

  Visual acuity declined roughly linearly with time, with a sharper decline in people who already had reduced vision and more than 10 years of disease.

  Why it matters:

  Understanding the natural course helps set realistic expectations and provides a baseline for judging whether treatments help.

  Limitation: It combines different studies with varied methods, and East Asian populations were more heavily represented.

BCD is inherited recessively, so an affected person's siblings each have a chance of being affected or of being unaffected carriers, and genetic counseling can help relatives understand their own situation. Because symptoms often begin and progress during adulthood and working years, families may want to plan ahead for changes that affect employment and independence. Beyond these points, the general caregiver guidance shown on every gene page applies.

• Does my genetic result confirm biallelic (two-copy) CYP4V2 changes, and what is known about the specific variants I carry?
• Which imaging and functional tests would best track how my vision is changing over time?
• Given my current vision and disease stage, what does the typical range of progression look like?
• Are there any BCD-related eye complications, such as macular edema, that should be monitored?
• Would genetic counseling be helpful for my relatives or for family planning, given the recessive inheritance?
• Are there gene therapy clinical trials for BCD that I might be a candidate to discuss, and how would eligibility be assessed?

Confirming the diagnosis with genetic testing and, where possible, identifying the specific CYP4V2 variants can help clarify the diagnosis and inform family planning discussions. A retinal specialist can use imaging such as optical coherence tomography (definition: An imaging test (often abbreviated OCT) that creates a detailed, layer-by-layer picture of the retina without touching the eye.) and autofluorescence to document the state of the retina and monitor changes over time. Because gene therapy (definition: A treatment that delivers a working copy of a gene into cells to take over for a copy that isn't functioning properly.) research for BCD is advancing quickly, it may be useful to discuss current clinical trials and their requirements with a specialist familiar with inherited retinal disease. RP Hope's resources for newly diagnosed people and its guided pathway can help you understand genetic testing and plan next steps.